Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Mercury Pharmaceuticals Ltd, Capital House, 85 King William Street, London, EC4N 7BL, UK
Non-selective Monoamine Oxidase Inhibitor:
ATC code: N06AF04
Tranylcypromine is a non-Hydrazine monoamine oxidase inhibitor.
Tranylcypromine is well and rapidly absorbed after oral administration.
Peak plasma levels are reached after about 2.5 hours and the half life is of the order of 2 hours.
Tranylcypromine undergoes considerable metabolism, including breakdown of the side chain and probably conjugation. The main action of this compound is irreversible inhibition of MAO (both MAOA and MAOB) this lasts for some time, and clinically is considered to have reversed within 14 days.
Excretion is pH dependent.
None stated.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
